Amarin Corp. Plc said on Monday the company would cut its workforce by 40 percent, as the drugmaker’s fish-oil derived heart drug faces stiff competition from generic rivals in the United States.
https://www.pharmalive.com/wp-content/uploads/2022/06/KarimMikhailAmarin.jpg430576Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-06 10:16:572022-06-06 11:48:00Amarin to slash jobs as generic rivals dull U.S. prospects of heart drug